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Executive Summary
Cost-effectiveness analysis, even with its inherent methodological problems, consistently shows that
when smoking cessation interventions are effective they are invariably also cost-effective. This is largely
due to their relative low cost and the big impact that stopping smoking has on health outcomes.
This is also the case for pharmacotherapy for smoking cessation, including nicotine replacement therapy
(NRT), bupropion (Zyban) and varenicline (Champix).
There is evidence that varenicline may be more cost-effective than other pharmacotherapy. Evidence
is less conclusive about the relative cost-effectiveness of NRT compared with bupropion. Combination
therapy (several forms of NRT, or NRT and bupropion) is also cost-effective compared with brief advice
or counselling alone. While it is likely that combination pharmacotherapy, as compared with mono-
pharmacotherapy, is cost-effective it has not yet been directly evaluated.
Findings from economic analyses from the UK and elsewhere confirm that smoking cessation interventions,
including pharmacotherapy, are among the most cost-effective health care interventions available.
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Key points
1. Cost-effectiveness overview
1.1  Definitions and methodology
■ Cost-effectiveness compares the impact of two or more alternative courses of action with
regards to their costs and benefits. Within the health care setting such cost-effectiveness
analysis (CEA) usually focuses on the additional cost per additional unit of health gain
created by one compared with another intervention: the incremental cost-effectiveness
ratio (ICER).1
■ In contrast to cost benefit analyses, where health-related consequences are expressed in
monetary terms, CEA uses either life-years (LY) or quality adjusted life years (QALY) gained.2
The former simply counts the additional years added to a person’s life due to an intervention,
while the latter weights these years according to the perceived life quality in terms of a number
of factors such as pain / discomfort, mobility and mental well-being.3 Each QALY is assigned
a value between 1.0 (perfect health) and 0.0 (death). However, in smoking cessation research
CEA values greater than 1.0 have been applied as stopping smoking not only reduces
mortality but also chronic morbidity; thus a chronic morbidity component has been added.4
■ CEA additionally takes into consideration the fact that the worth of extended life in the
future is considered to be less than if immediately realised, due to the uncertainties we
associate with future events.5 Each LY or QALY is therefore discounted by a fixed amount
per year, typically between 1.5% – 3.5%.6
1.2  NICE Guidance
■ The National Institute for Health and Clinical Excellence (NICE) is charged with evaluating
the effectiveness as well as cost-effectiveness of treatments in order to make recommendations
about the implementation in the UK National Health Service (NHS).7
■ NICE has adopted a cost-effectiveness threshold of £20,000 – £30,000 per QALY above
which interventions are unlikely to be recommended. However, there is much debate about
the correct level of this threshold which is considered implicit rather than explicit8 and
varies enormously between countries.9 In fact, in NHS settings the cost-effectiveness
threshold for circulatory diseases and cancers is below £20,00010, whilst NICE
recommendations in practice have a much higher threshold.11
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1.3  Caveats
■ CEA is ubiquitously used by decision makers. However, there are considerable differences in
outcomes of CEA due to the various assumptions necessary to predict future health benefits.12
■ There are four main problems of CEA that need to be borne in mind when
interpreting results.2,13
1) QALY: can health be adequately expressed in economic terms at all? Methods require
that subjective ratings from many people are aggregated into a single measure.
2) Costs / uncertainty: how should intersectoral, wider societal costs be evaluated?
It is likely that an intervention may have unintended positive or negative costs
not considered.
3) Discounting: what is the right threshold? Higher rates will favour acute interventions
over preventative interventions and thus put more value on treatments for the elderly.
4) Equity: how can the needs of different patient populations (e.g. those from lower
socio-economic groups, those with greater clinical need) be accurately captured?
Differential weighting of costs by QALY for different populations may be applied.
2. Cost-effectiveness of single pharmacotherapy
There are three principal forms of pharmacotherapy available on prescription for smoking 
cessation in the UK.
2.1 Nicotine Replacement Therapy (NRT)
■ NRT delivers nicotine either through the skin, nasal or buccal mucosa to reduce cravings
and withdrawal symptoms, and the rewarding effects of smoking as well as providing some
behavioural control.14  It is available in seven forms (gum, patch, inhaler, lozenge, sublingual
tablet, nasal or mouth spray). NRT has been found to be very effective, roughly doubling
a smoker’s chances of remaining abstinent.15
■ The cost per quitter for brief advice and NRT has been estimated between £267 in 199716
and £649 in 1999.17  Most recently, in 2002, the cost per lifetime quitter was put between
£1,173 and £2,288.18 Cost-effectiveness estimates in the UK vary equally widely for NRT
with ICER ranging more than 10-fold from £350 in 199819 to £4,500 per LYS in 1994 20
compared with brief GP advice alone; estimates from the US are similarly diverse.4 The ICER
of NRT was estimated in 2002 to range between £494 and £3,554 per QALY depending on
the comparator and assumptions for QALY saved (see Figure 1).18 Despite this range in
estimates, all CEA conclude that NRT is highly cost-effective and this is reflected in
NICE guidance.21
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Figure 1: Incremental cost effectiveness ratio of pharmacotherapy and brief advice or
counselling compared with brief advice or counselling alone.
*Comparator; **Based on one study only22
Please note where appropriate prices have been converted to GBP
2.2 Bupropion (Zyban)
■ Bupropion is an atypical antidepressant which acts on dopamine and noradrenaline pathways
and possibly as a nicotinic antagonist, thus reducing withdrawal symptoms and the rewarding
effects of smoking.23 Bupropion is a very effective smoking cessation aid, increasing smoking
cessation rates by around 70% compared with placebo.24
■ In the UK, the cost per life-time quitter for bupropion has been estimated at between £964
and £1,799 in 2002,18 roughly equivalent to the costs in the US.25 The ICER of bupropion
is equally favourable, estimated at around £830 per QALY in the US in 2005 compared with
brief advice.26 In the UK, this figure varies between £316 and £2,212 depending on the
comparator and assumptions (see Figure 1). There is also some evidence that bupropion is
more cost-effective than NRT when considering the ICER of these interventions27 and in direct
comparison (see Figure 2).28 These results need to be interpreted with caution, however,
as this was only observed in comparison with the nicotine patch, not gum, and was derived
from different countries so may therefore not straightforwardly translate to the UK. It is clear,
however, that bupropion is very cost-effective and is therefore recommended as a first-line
treatment by NICE guidelines.
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Figure 2: Incremental cost effectiveness ratios between different pharmacotherapy.
*Based on one study only28
Please note where appropriate prices have been converted to GBP
2.3 Varenicline (Champix)
■ Varenicline includes the active substance cytisine which acts as a partial nicotinic acetylcholine
receptor agonist with high affinity for the α4β2 receptor subtype. It reduces withdrawal
symptoms and the rewarding effects of smoking by competing with nicotine to activate these
receptors.29 Varenicline has been shown to be highly effective, increasing the odds of long-
term smoking cessation three-fold compared with quit attempts not aided by pharmacotherapy.30
In direct comparison, it also appears to be more effective than bupropion but, to date,
not NRT.30
■ The cost per additional quitter for varenicline is approximately £2,170.31 The ICER of varenicline
compared with no pharmacotherapy has been estimated at between £95032 and £1,14022
per QALY gained, varying as a function of various assumptions. It is very cost-effective compared
with minimal advice22 (see Figure 1). Varenicline has been shown to be more cost-effective
than either NRT or bupropion in the UK33 and elsewhere,34,35 though estimates vary greatly
due to different methodologies applied (see Figure 2). Prolonging treatment duration from
12 to 24 weeks has also been shown to be cost-effective, resulting in an ICER of £622 per
QALY.36  Varenicline is therefore endorsed as effective and cost-effective treatment for smoking
cessation by NICE guidelines.21
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3. Cost effectiveness of combined pharmacotherapy
■ Monotherapy has been shown to be effective. However, more than two thirds of smokers
will have relapsed by one year.15,24,30 The rationale for combined pharmacotherapy is that
medication may have synergistic effects when therapies with different pharmacological targets
(e.g. NRT and bupropion) or different pharmacological profiles (e.g. nicotine patch and
nicotine gum) are combined.37
■ The combination of different forms of NRT has been shown to increase abstinence rates
compared with single NRT.15,38 Evidence for the combination of NRT with bupropion is
less equivocal, suggesting an increase in short-term but not long-term abstinence compared
with monotherapy.39 Whilst there is some evidence that the combination of varenicline with
bupropion,40 and less so with NRT,41 may be beneficial, there is currently insufficient
evidence to draw firm conclusions.
■ The combination of NRT and bupropion is cost effective compared with minimal advice
(ranging between £973 – £2,918 per QALY gained) and counselling alone (range £440 – £1,319).18
Evidence of combining NRT, bupropion and counselling compared with bupropion and
counselling alone is weaker, suggesting only a marginal or no additional benefit.27 However,
one piece of indirect analysis comparing combination NRT with single NRT found a benefit 
and suggests an incremental cost per quitter at long-term follow-up of between £2,500 and
£6,825.37 A similar result is obtained when comparing NRT and bupropion with single NRT
alone (range £2,000 – £6,200).27;37 Both values compare favourably with the cost per quitter
of monotherapy added to counselling.
■ Given the relatively low cost of pharmacotherapy and the enormous health benefits of
stopping smoking, smoking cessation interventions are considered among the most cost-
effective available in the health care sector.42 Whilst there are no direct economic evaluations
of combination therapy, it is likely that even the small but significant benefits gained
from combination rather than monotherapy would be translated in cost-effective outcomes
compared with other health interventions for the treatment of smoking-related diseases
(see Figure 3).6
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Figure 3: UK spend per QALY gained for treatments of smoking-related diseases in primary /
secondary care compared with pharmacotherapy for smoking cessation.
Data from 10;18;43;44
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